Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accounts Payables (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Accounts Payables for 4 consecutive years, with $65.5 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 8.97% to $65.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.5 million through Dec 2025, down 8.97% year-over-year, with the annual reading at $65.5 million for FY2025, 8.97% down from the prior year.
  • Accounts Payables hit $65.5 million in Q4 2025 for Axsome Therapeutics, up from $54.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $170.9 million in Q2 2025 to a low of $12.6 million in Q1 2022.
  • Historically, Accounts Payables has averaged $63.5 million across 4 years, with a median of $54.0 million in 2024.
  • Biggest five-year swings in Accounts Payables: skyrocketed 319.88% in 2024 and later plummeted 55.62% in 2025.
  • Year by year, Accounts Payables stood at $51.6 million in 2022, then dropped by 21.21% to $40.7 million in 2023, then skyrocketed by 76.99% to $72.0 million in 2024, then fell by 8.97% to $65.5 million in 2025.
  • Business Quant data shows Accounts Payables for AXSM at $65.5 million in Q4 2025, $54.2 million in Q3 2025, and $170.9 million in Q2 2025.